Abstract pp52 (LSP1) is a leukocyte-speci®c phosphoprotein that binds the cytoskeleton and has been implicated in affecting cytoskeletal remodeling in a variety of leukocyte functions, including cell motility and chemotaxis. The expression of pp52 is restricted to leukocytes by a 549 bp tissue-speci®c promoter. Here, we show that promoter fragments smaller than the 549 bp pp52 promoter have activity in ®broblasts where pp52 is not normally expressed. Speci®cally, a truncated construct (11 to 299) functioned as a basal promoter active in leukocytes and ®broblasts. We identi®ed two upstream regions within the 549 bp pp52 promoter responsible for restricting pp52 promoter activity in ®broblasts. These two regions contained a silencer (pp52 NRE) and an anti-silencer (pp52 anti-NRE) with opposing activities controlling pp52 gene expression. The pp52 NRE was active in both leukocytes and ®broblasts while the pp52 anti-NRE was only active in leukocytes, thereby allowing pp52 gene transcription in leukocytes but not in ®broblasts. The pp52 NRE was localized to an 89 bp DNA segment between 2324 and 2235 in the 549 bp pp52 promoter and functioned as an active silencer element in a position and orientation independent manner. The pp52 anti-NRE was localized to a 33 bp segment between 2383 and 2350 of the 549 bp pp52 promoter and acted as an anti-silencer element against the pp52 NRE, but lacked any intrinsic enhancing activity on its own. These ®ndings indicate that the tissue speci®city of the pp52 promoter is determined by the pp52 anti-NRE anti-silencer which over-rides the general inhibitory activity of the pp52 NRE silencer. q
Introduction
The pp52 gene, also isolated as LSP1 (Jongstra et al., 1988; Jongstra-Bilen et al., 1990) and WP34 (Kadiyala et al., 1990) , encodes a 52 kilodalton leukocyte-speci®c intracellular phosphoprotein implicated in affecting cytoskeletal architecture and function (Jongstra-Bilen et al., 1990 . All B-lineage cells, granulocytes, macrophages, and primary T cells express pp52 mRNA (Jongstra et al., 1988; Gimble et al., 1993; Howard et al., 1994; Jongstra et al., 1994; Li et al., 1995) . However, pp52 mRNA is not expressed in some transformed murine T cell lines, and is found at extremely low levels in a subset of transformed human T cell leukemias (Jongstra et al., 1988; JongstraBilen et al., 1990; Kadiyala et al., 1990) . The pp52 protein binds ®limentous actin (F-actin) and co-caps with the B cell antigen receptor following surface immunoglobulin cross linking with anti-Ig antibody (Klein et al., 1990; JongstraBilen et al., 1992) . Through F-actin binding and membrane localization, pp52 potentially links the cytoskeleton with the cytoplasmic face of the plasma membrane (Klein et al., 1989) . Elevated pp52 expression is implicated in the rare genetic disorder, neutrophil actin dysfunction (NAD) (Howard et al., 1994) . NAD neutrophils have extended Factin-rich surface projections, abnormal cellular morphology, and impaired motility (Howard et al., 1994 (Howard et al., , 1998 . A recent study has shown that the impairment of leukocyte motility is directly related to the degree of pp52 elevation (Li et al., 2000) . Other recent ®ndings indicate that elevated pp52 expression levels are correlated with the distinctive spiky projections found in Hairy Cell Leukemia where the leukemic B cells strikingly resemble the affected neutrophils in NAD (Miyoshi et al., 2001) .
Leukocyte-speci®c pp52 transcription is driven by a TATA-less promoter which initiates from a single start site determined by an initiator element (Inr) (Thompson et al., 1996; Omori et al., 1997) . The 549 bp pp52 promoter is strictly tissue speci®c and is therefore highly active in B cells and T cells, but inactive in 3T3 ®broblasts. Duplicated Ets and Sp1 binding motifs and a single central C/EBP factor binding site are critical for tissue-speci®c pp52 (2549) promoter activity (Fig. 4 and Omori et al., 1997) . However, these factors are not speci®c to leukocytes, leaving open the question of how the strict tissue-speci®city of the pp52 promoter is determined.
Here, we describe a mechanism for regulating tissuespeci®c expression of the pp52 (2549) promoter. We noted that pp52 promoter fragments smaller than the pp52 (2549) leukocyte-speci®c promoter lost tissue speci®city and were expressed in ®broblasts, albeit at lower levels than in B cells. The region from 299 to 11 containing the Ets and Sp1 motifs functioned as a basal promoter in B cells and ®broblasts. Deletion series of the pp52 (2549) promoter also revealed a region that reduced expression of the pp52 promoter in both B cells and ®broblasts, and a region that restored activity to leukocytes but not to ®bro-blasts. These data suggested a silencer/anti-silencer interplay controlling pp52 tissue-speci®c expression. Silencer elements are de®ned as cis -acting DNA regulatory elements that down regulate gene transcription (Chen et al., 1993; Young and Korsmeyer, 1993; Martensson and Melchers, 1994; Ernst and Smale, 1995) , while anti-silencer elements have been shown to restore gene activity to pre-silencer levels by over-riding silencer activity (Stover and Zehner, 1992; Ferradini et al., 1994; Dobretsova and Wight, 1999; Izmailova and Zehner, 1999) . Our results suggest that the pp52 anti-NRE (i.e. anti-silencer) counteracts the pp52 NRE silencer in leukocytes to support pp52 expression in leukocytes. Since the pp52 anti-NRE is not active in ®broblasts, it therefore cannot counteract the silencing activity of the pp52 NRE, which restricts pp52 expression in ®broblasts.
Materials and methods

Cells, DNA transfections, and CAT assays
All cell lines were propagated in RPMI 1640 supplemented with sodium pyruvate (GibcoBRL, Gaithersberg, MD), non-essential amino acids (GibcoBRL), 50 mM b-ME (Sigma Chemicals, St. Louis, MO), 5 mM glutamine (Sigma), and 5% fetal calf serum (FCS, Omega Scienti®c, Tarzana, CA). 1 £ 10 7 M12 B cells were co-transfected with 5 mg of CAT constructs and 1 mg of pRSV-luciferase by the DEAE-dextran method as described (Grosschedl and Baltimore, 1985) . 3-1 pre-B cell line, BW5147 T cell line, and EL-4 T cell line were transfected by electroporation as previously described . NIH 3T3 ®bro-blasts and Raw264 macrophage cell line were transfected using the calcium phosphate method (Ausubel et al., 1994) with one modi®cation. Precipitated DNA (5 mg of CAT constructs and 4 mg of pRSV-luciferase) was added to 70% con¯uent monolayers in 100 mm dishes whose media had been replaced by DMEM plus 5% Transfector II (modi®ed bovine serum (MBS), Stratagene, La Jolla, CA) immediately prior to transfection. Cells were incubated for 3 h at 378C, 5% CO 2 , washed three times with 1 £ PBS, and grown in supplemented RPMI plus 5% FCS. All transfections were harvested 40±48 h after transfection. Extracts were prepared and CAT assays performed as described previously (Omori and Wall, 1993) . Quantitations were done using a Molecular Dynamics Phosphorimager.
Plasmid construction and deletion mutagenesis
The pp52 (2549) and pp52 (2350) deletion constructs were generated using internal Xba1 and EcoR1 sites, respectively, found in the original pp52 (21.0 kb) construct previously described (Thompson et al., 1996) . All deletion fragments were subcloned into pCAT-Basic (Promega, Madison, WI) and indicated by number of bases from the start site of transcription (11). The pp52 (2307), pp52 (2293), pp52 (2257), pp52 (2204), and pp52 (299) deletions were generated by exonuclease III/mung bean nuclease (Stratagene) digestion of the pp52 (2350) promoter fragment CAT construct. The pp52 endogenous ATG was destroyed leaving the ®rst methionine of the CAT gene as the translational start site. For the negative regulation studies, an 89 bp Alu1 fragment encompassing the potential silencer region was ligated to HindIII linkers and subcloned 5 H of the pp52 (299) promoter construct. pp52 (2350-NRE) and pp52 (2549-NRE) promoter constructs were generated by creating EcoRV restriction sites at 2324 and 2235 using the Quik-Change mutagenesis kit (Stratagene) in the pp52 (2350) and (2549) promoter constructs, excising the intervening sequences by restriction digest, and religation of the resulting plasmid minus 2324 to 2235 putative silencer sequences.
Nuclear extracts and DNA-binding assays
Preparation of crude nuclear extracts from cell lines were prepared as described (Lo et al., 1991) . DNase 1 protection assays were performed as described (Lo et al., 1991 H ) and subsequent pfu (Stratagene) PCR cycling at 958C, 30 s; 558C, 1 min; 728C, 2 min; using the pp52 2549 plasmid construct as the template. DNase 1 protection probes were puri®ed by StrataPrep PCR puri®cation kit (Stratagene). EMSA was performed as described (Omori and Wall, 1993) with the exception of 5 mg poly(dI´dC) and 4.5% polyacrylamide/bis-acrylamide 60:1 and 0.5 £ TBE (22 mM Tris base, 7 mM boric acid, 0.5 mM EDTA pH 8). Gels were run at 125 V for 2.5 h at room temperature. pp52 NRE EMSA probes were Alu1 DNA restriction fragments (2324 to 2235) labeled at both 5 H ends with [g-32 P]ATP. pp52 anti-NRE probes were the following double-stranded complementary oligonucleotides: 5 H -AGCAGTCCACGGACACTAAAGGGACCATGAATT-3 H (pp52 anti-NRE). pp52 NRE and pp52 anti-NRE EMSA probes were puri®ed by G50 and G25 sephadex spin column chromatography, respectively.
Results
pp52 promoter deletion analysis suggests the presence of silencer elements
Previously, we reported that the pp52 promoter fragment (2549) is tissue-speci®c and only active in leukocyte cell lines. This pp52 promoter fragment (2549) had little or no activity in 3T3 ®broblasts . In order to identify regions of potential tissue-speci®c activity, we tested two additional deletion constructs in a pre-B cell line (3-1), a B cell line (M12), two T cell lines (BW5147 and EL-4), a macrophage cell line (Raw264), and a ®bro-blast cell line (NIH 3T3). Table 1 shows that leukocytespeci®city is lost upon deletion to the 299 bp pp52 promoter. The 299 pp52 promoter construct was expressed in 3T3 ®broblasts where the 2549 pp52 promoter construct was not. Interestingly, the 2350 pp52 promoter construct was not expressed well in any of the cell lines, suggesting that silencer elements may play a role in pp52 promoter regulation. To further delineate the putative silencer region and the tissue-speci®c promoter, a deletion series between 2549 and 299 was generated giving rise to pp52 (2473), pp52 (2428), pp52 (2383), pp52 (2350), pp52 (2307), pp52 (2257), pp52 (2204), and pp52 (299). These were tested in the B cell line M12 and the ®broblast cell line 3T3. A substantial and reproducible loss of leukocyte-speci®c regulation of the pp52 promoter occurred upon deletion of 5 H sequences 2257 bp and smaller to 299 bp (Fig. 1A) . These truncated pp52 promoter fragments (2257, 2204, and 299) allowed statistically signi®cant pp52 promoter activity in 3T3 ®broblasts (Fig. 1A) . In contrast, these pp52 promoter construct activities were unaltered compared to the leukocyte-speci®c pp52 (2549) promoter in the M12 B cell line (Fig. 1B) . These data also indicate that the pp52 (299) fragment is the basal pp52 promoter.
Interestingly, the deletion constructs pp52 (2307) and pp52 (2350) showed signi®cantly decreased activity compared to the pp52 (299) in both B cells and ®broblasts, suggesting that there may be tissue-restricting silencer elements within the region between 2257 and 2383 of the pp52 promoter (Fig. 1A,B) . Fig. 1A ,B suggest that the putative pp52 silencer element(s) were able to down regulate transcription in both B cells and ®broblasts. Fig. 1A ,B show that the 2383 fragment of the pp52 promoter was highly active in M12 B cells but not active in 3T3 ®bro-blasts. These data suggest that there may be sequence elements within the pp52 (2383) fragment that can counteract the effects of the negative regulatory 2257 to 2350 region in B cells, but not in ®broblasts (Fig. 1A,B) . These studies suggest that the pp52 promoter contains both silencer (pp52 NRE) and anti-silencer (designated pp52 anti-NRE) elements that control its tissue-speci®c expression (See Fig. 6 ).
The pp52 NRE and pp52 anti-NRE forms speci®c protein complexes in M12 B cell and 3T3 ®broblast nuclear extracts
We tested the pp52 NRE and the pp52 anti-NRE elements for their ability to interact with DNA-binding proteins. Fig.  2 shows that DNA-binding proteins from both M12 B cell and 3T3 ®broblast nuclear extracts form a complex with the 89 bp pp52 NRE. While this complex was speci®cally competed away by excess unlabeled pp52 NRE probe, unlabeled oligonucleotides corresponding to the consensus binding site for the YY1 silencer element (Galvin and Shi, 1997) were unable to act as competitors (Fig. 2) . In addition, the pp52 NRE protein complex was not competed away by several known silencer element binding motifs including the ubiquitous B29 gene silencer sites TOAD, FROG, and A 1 T-rich motif (data not shown). The 33 bp pp52 anti-NRE also forms speci®c protein complexes with both M12 B cell and 3T3 ®broblast nuclear extracts (Fig. 3) . These complexes are speci®cally competed away by excess unla- (2549) promoter construct and are the averages of at least three independent transfections. All values were normalized to RSV luciferase activity. M12 is a B cell line, 3-1 is a pre-B cell line, BW5147 is a T cell line, EL-4 is a T cell line, Raw264 is a macrophage cell line, and NIH 3T3 is a ®broblast cell line.
b Absolute fold inductions of pp52 (2549) over pCAT basic for the above cell lines ranged from: 10±21 fold for M12; 14±26 fold for 3-1; 17±40 fold for BW5147; 22±54 fold for EL-4; 29±98 fold for Raw264; and 1±3 fold for NIH 3T3.
c CAT activities expressed as the percentage of the (299) promoter. Absolute fold inductions of pp52 (299) over pCAT basic ranged from 4± 11 fold. beled pp52 anti-NRE oligonucleotides, but are not competed away by unlabeled pp52 NRE fragment (Fig. 3) . These data suggest that the pp52 NRE and the pp52 anti-NRE elements interact with differing protein complexes.
3.3. The pp52 NRE acts as a position and orientation independent silencer element Silencer elements are often inhibitory elements that function in a position and orientation independent manner (Cao et al., 1989; Farrell et al., 1990; Sawada et al., 1994) . To determine whether the pp52 promoter has silencer element activity, an 89 bp Alu1 restriction fragment encompassing most of the transcriptionally inhibited region, 2325 to 2234 designated the pp52 NRE, was taken out of context and subcloned immediately 5
H of the pp52 (299) minimal promoter construct. As shown in Fig. 4 , the pp52 NRE inhibited the activity of the pp52 (299) promoter to the levels of the relatively inactive pp52 (2350) fragment in both B cells and ®broblasts. Additionally, the pp52 NRE was able to exert silencing activity in both the forward and reverse orientations (Fig. 4) . These data suggest that the pp52 NRE is a position and orientation independent silencer element. Furthermore, three-fold multimerization of this fragment increased inhibition of the pp52 (299) construct in both ®broblasts and B cells, suggesting an addi- Fig. 2 . The pp52 NRE interacts with DNA-binding proteins. Doublestranded DNA restriction fragment (Alu1) corresponding to the pp52 promoter sequence 2324 to 2235 with respect to the transcriptional start site of the pp52 gene was end-labeled and used in EMSA. Lane 1 contains pp52 NRE probe alone while lanes 2±4 and 5±7 contain pp52 NRE probe incubated with 20 mg M12 B cell nuclear extract and 20 mg NIH 3T3 ®broblast nuclear extract, respectively. Probe was also coincubated with 500-fold excess of unlabeled pp52 NRE probe (lanes 3 and 6) and with 500-fold excess of unlabeled YY1 consensus binding site (lanes 4 and 7) . Speci®cally formed complex is indicated by an arrow and is representative of at least three independent experiments. Unbound probe is indicated by an arrow labeled with`Free pp52 NRE probe'. Fig. 1 . pp52 deletion analysis suggests the presence of silencer and antisilencer elements that control tissue-speci®city. Transient transfection to detect transcriptional expression of pp52 promoter deletion constructs. Deletion constructs are identi®ed by nucleotide number with respect to the start site of transcription (11). The activity of each construct is expressed as fold induction above pCAT basic promoterless construct. CAT activities are RSV-luciferase normalized and are the averages^SD of six independent transfections using at least three preparations of DNA. (A) Transient transfections were conducted in the NIH 3T3 ®broblast line (black bars). The Student's two sided t-test P values for deletion constructs with respect to the tissue-speci®c pp52 2549 construct are as follows: 299: P , 0.05; 2204: P , 0.05; 2257: P , 0.05; 2307: P . tive effect of multiple elements (Fig. 4) . Conversely, when the pp52 NRE was placed 5
H of the SV40 early promoter (pCATpromoter, Promega), no inhibitory activity was observed (data not shown). Therefore, the pp52 NRE appears to be an active silencer element in multiple cell types, but it may be speci®c for pp52 and not active against heterologous promoters. Several other silencer elements appear to be gene speci®c as well, including those in the b-type globin gene, the osteocalcin gene, and the mouse and human IL-4 gene (Li-Weber et al., 1992; Bruhn et al., 1993; Frenkel et al., 1994; Wandersee et al., 1996) .
Deletion of the pp52 NRE from the pp52 promoter constructs results in alleviation of silencing activity
The pp52 NRE (2324 to 2235) was deleted from the pp52 (2350), pp52 (2383), pp52 (2428), pp52 (2473), and pp52 (2549) promoter constructs to clarify the role of the pp52 NRE in the leukocyte-speci®c regulation of the pp52 gene and to determine whether anti-silencer elements were present upstream of the pp52 NRE. These constructs were tested for transcriptional activity in transient transfection of NIH 3T3 ®broblasts and M12 B cells. Fig. 5A shows that the inhibitory effects of the pp52 NRE in 3T3 cells were reversed upon the removal of the pp52 NRE, con®rming that the pp52 NRE sequence was responsible for the silencing of the pp52 promoter constructs in ®broblasts. These data therefore suggest that the pp52 NRE controls the leukocyte-speci®c activity of the pp52 promoter. Fig. 5B shows that the inhibitory effects of the pp52 NRE in B cells were reversed upon removal of these sequences in the pp52 (2350-NRE) promoter, con®rming the observation from Fig. 1 that the pp52 NRE functions as a silencer element in B cells as well as in ®broblasts. Removal of the pp52 NRE in the other pp52 promoter constructs (2383-NRE, 2428-NRE, 2473-NRE, and 2549-NRE) in B cell transfections showed no signi®cant difference from the comparable wild type promoter construct (2383, 2428, 2473, 2549) (Fig. 5B) . These data are consistent with the observation from Fig. 1 that the pp52 NRE exerts no silencing activity in the pp52 (2383), pp52 (2428), pp52 (2473), and pp52 (2549) promoter constructs in B cells. Additionally, no signi®cant difference in promoter activity between the wild type and the NRE deletion mutant constructs (e.g. 2383 versus 2383-NRE) was observed, suggesting that the pp52 anti-NRE has no inherent enhancer activity, and can therefore be de®ned as an anti-silencer element. Together, these results suggest that the pp52 anti-NRE anti-silencer element was active in B cells, but not in ®broblasts. Collectively, these data suggest that the 2324 to 2235 pp52 NRE Fig. 3 . The pp52 anti-NRE probe interacts with DNA-binding proteins. Double-stranded oligonucleotides corresponding to the pp52 promoter sequence 2383 to 2350 with respect to the transcriptional start site of the pp52 gene were end-labeled and used in EMSA. Lanes 1±3 contain the pp52 anti-NRE probe incubated with 20 mg M12 B cell nuclear extract and lanes 4±6 contain the pp52 anti-NRE probe incubated with 20 mg NIH 3T3 ®broblast nuclear extract. Probe was also coincubated with 500-fold excess of unlabeled pp52 anti-NRE probe (lanes 2 and 5) and with 500-fold excess of unlabeled pp52 NRE probe (lanes 3 and 6). Speci®cally formed complexes are indicated by arrows and are representative of at least three independent experiments. Unbound probe is indicated by an arrow labeled with`Free pp52 anti-NRE probe'. Fig. 4 . The pp52 NRE acts as a position and orientation independent silencer element. Transient transfections to detect transcriptional expression of pp52 promoter/NRE constructs were conducted in the M12 B cell line (gray bars) and NIH 3T3 ®broblast line (black bars). The pp52 NRE fragments and the position and orientation relative to the pp52 (299) promoter are as indicated. Deletion constructs 299, 2350, and 2549 are identi®ed by nucleotide number with respect to the start site of transcription (11) and are shown for comparison. The activity of each construct is expressed as fold induction above pCAT basic promoterless construct. CAT activities are RSV-luciferase normalized and are the averages^SD of six independent transfections using at least three preparations of DNA. The Student's two sided t-test P values for deletion constructs with respect to the minimal pp52 299 construct are as follows: single NRE forward, M12: P , 0.05, 3T3: P , 0.05; single NRE reverse, M12: P , 0.05, 3T3: P , 0.05; triple NRE forward, M12: P , 0.05, 3T3: P , 0.05; 2350, M12: P , 0.05, 3T3: P , 0.05; and 2549, M12: P . 0.05, 3T3: P , 0.05. Statistically signi®-cant values are signi®ed with an asterisk (*). silencer element is solely responsible for shutting off pp52 expression in ®broblasts while the pp52 anti-NRE antisilencer element between 2350 and 2383 overcomes the pp52 NRE silencer element activity in B cells and allows promoter activity.
Discussion
Our studies delineate a silencer/anti-silencer cassette located within the 549 bp leukocyte-speci®c pp52 promoter that restricts basal promoter (299 to 11) activity in nonleukocyte cells (see Fig. 6 ). We have narrowed the pp52 silencer region to an 89 bp fragment (pp52 NRE, 2324 to 2235) and have shown that this fragment alone, out of context and in either orientation, was suf®cient to inhibit the activity of the pp52 (299) promoter in ®broblasts and B cells. The activity of this pp52 silencer element in B cells, where pp52 is normally expressed, places the pp52 NRE into an emerging class of transcription silencer elements which are also active within their own cell lineages. This silencer family includes B29 (Malone et al., 1997) , bcl-2 (Young and Korsmeyer, 1993) , huETS-1 (Chen et al., 1993) , and l5 (Martensson and Melchers, 1994; Yang et al., 1995) . Interestingly, all of these known silencers control genes that have TATA-less promoters (Dynan and Tjian, 1983; Oka et al., 1991; Omori and Wall, 1993; Martensson and Melchers, 1994) . Unlike these other silencers, the pp52 silencer activity appears to be overcome by 5
H sequences in B cells where pp52 is expressed, but not in ®broblasts where pp52 is not normally expressed. Such results are indicative of anti-silencer activity conferring tissue-speci®c transcriptional control (Stover and Zehner, 1992; Ferradini et al., 1994; Dobretsova and Wight, 1999; Izmailova and Zehner, 1999) . This anti-silencer was located between 2350 and 2383 in the pp52 promoter (pp52 anti-NRE) and allowed activity of the 2383 and larger pp52 promoter constructs in B cells. This anti-NRE was not active in ®broblasts, and therefore did not derepress the pp52 promoter construct containing the pp52 NRE (e.g. 2383, 2472, 2549). The pp52 promoter was only expressed in ®broblasts with constructs lacking the pp52 NRE such as the 2207 and 299 promoter constructs, or when the pp52 NRE (2324 to 2235) was deleted from the 2383 and larger pp52 promoter constructs. These data suggest the pp52 NRE is responsible for the inhibition of pp52 expression in ®bro-blasts. In B cells, the pp52 (2549) promoter is highly active regardless of the presence of the pp52 NRE, when the pp52 anti-NRE is present. Anti-silencer elements have the ability to over-ride transcriptional inhibition by silencer elements, but have no innate enhancer activity on their own (Stover and Zehner, 1992; Ferradini et al., 1994; Dobretsova and Wight, 1999; Izmailova and Zehner, 1999) . The pp52 promoter clearly ®ts this anti-silencer criteria as it overrides the pp52 NRE, but it does not substantially increase or enhance the activity of the pp52 basal promoter.
Several functional silencer elements and anti-silencer elements are reported to interact with DNA binding proteins (Stover and Zehner, 1992; Ferradini et al., 1994; Ernst and Smale, 1995; Dobretsova and Wight, 1999; Izmailova and Zehner, 1999) . DNase 1 protection analyses over a large portion of the pp52 promoter failed to delineate a limited region of DNA binding activity, and instead predicted a Constructs with the deletion of the pp52 NRE are indicated by having a gap in the promoter construct and by being labeled with`-NRE', e.g.`-350-NRE'. Deletion constructs 299, 2350, 2383, 2428, 2473 , and 2549 are identi®ed by nucleotide number with respect to the start site of transcription (11) and are shown for comparison. The activity of each construct is expressed as fold induction above pCAT basic promoterless construct. CAT activities are RSV-Iuciferase normalized and are the averages^SD of six independent transfections using at least three preparations of DNA. The Student's two sided t-test P values for deletion constructs with respect to their corresponding promoter construct containing the NRE are as follows: 2350-NRE, M12: P , 0.05, 3T3: P , 0.05; 2383-NRE, M12: P . 0.05, 3T3: P , 0.05; 2428-NRE, M12: P . 0.05, 3T3: P , 0.05; 2473-NRE, M12: P . 0.05, 3T3: P , 0.05; and 2549-NRE, M12: P . 0.05, 3T3: P , 0.05. Statistically signi®cant values are signi®ed with an asterisk (*). large protein complex spanning both the pp52 NRE and the pp52 anti-NRE (data not shown). In our EMSA analyses, the pp52 NRE fragment formed speci®c protein complexes in both M12 and 3T3 nuclear extracts in EMSA that appeared to have the same mobility and similar af®nity between the two cell types. These nuclear protein binding results support the functional data showing that the pp52 NRE is active in both B cells and ®broblasts. The identity of the protein(s) interacting with the pp52 NRE remains to be determined. EMSA using the de®ned 33 bp pp52 anti-NRE resulted in a differing pattern of speci®c protein complex formation in M12 and 3T3 nuclear extracts. These data suggest that the pp52 anti-NRE interacts with different proteins or protein complexes between the two cell types. These results support our functional data showing that the pp52 anti-NRE had differing activities in M12 B cells and 3T3 ®broblasts, possibly due to the differing protein complexes seen in EMSA.
The transient transfection functional data clearly demonstrated a role for both the pp52 NRE silencer and the pp52 anti-NRE anti-silencer in controlling pp52 gene expression. Similarly acting silencer and anti-silencer elements have been identi®ed within both the human and chicken intermediate ®lament vimentin gene promoters (Stover and Zehner, 1992; Izmailova and Zehner, 1999) , the chicken lambda light chain locus (Ferradini et al., 1994) , the myelin proteolipid protein gene (Dobretsova and Wight, 1999) , and the Escherichia coli gene RcsA (Sledjeski and Gottesman, 1995) . Like the pp52 anti-silencer, the human and chicken vimentin anti-silencer elements were shown to restore vimentin gene activity in cell types where the vimentin gene is expressed. Reminiscent of the fact that pp52 antisilencers do not function as enhancer elements, the vimentin gene anti-silencers also do not affect gene activity when their corresponding silencer element is absent (Stover and Zehner, 1992; Izmailova and Zehner, 1999) . Gene regulation of the lambda light chain is even more comparable to the mechanism we found for pp52 gene regulation. The tissue-speci®c lambda light chain gene rearrangement and subsequent transcription is controlled by a silencer/antisilencer interplay where the silencer element is active in both orientations in all cell types and the anti-silencer is only active in B cells (Ferradini et al., 1994) . The lambda light chain gene data suggest that during B cell development, only B cell precursors express the anti-silencer binding proteins that counteract the effect of the silencer, thereby allowing rearrangements and light chain gene transcription to occur. In the case of the pp52 gene, expression of factors that bind to the anti-NRE is presumably restricted to leukocytes. The interactions of such factors with the anti-NRE would over-ride the otherwise dominant inhibitory effects of the pp52 NRE silencer, thereby allowing pp52 gene expression only in leukocytes. These ®ndings add the pp52 gene to a growing list of genes in which anti-silencers control tissue-speci®c gene transcription by relieving normal gene repression mediated by non-tissue restricted silencers. Interestingly, this complex mode of gene regulation appears to be the rule rather than the exception for genes encoding proteins of highly specialized functions that are restricted to speci®c cell lineages. Fig. 6 . Schematic of the regulatory regions and transcription factors identi®ed within the pp52 promoter. The pp52 2549 tissue-speci®c promoter was identi®ed and characterized to be controlled by C/EBP, Ets, and Sp1 factors . Deletion analyses identi®ed the pp52 299 basal promoter, silencer (NRE) and anti-silencer (anti-NRE) segments. Anti-NRE and NRE elements are shown as they reside in the pp52 promoter relative to sequence number and to position of known transcription factor binding sites.
